This article is more than 5 years old. Information may no longer be current.
Intravitreal sirolimus resolves vitreous haze in SAKURA study 1
LAS VEGAS — Intravitreal sirolimus may significantly resolve vitreous haze in patients with no anterior segment involvement, according to a presentation here.
Pravin U. Dugel, MD, presented double-masked data of vitreous haze scores and steroid tapering success results of 347 patients with noninfectious uveitis of the posterior segment from month 5 of the SAKURA study 1 post hoc analysis at the American Academy of Ophthalmology annual meeting.
Pravin U. Dugel
The analysis included three active arms: 76 patients received 44 µg of intravitreal sirolimus as the active control, 70 patients received 440 µg of intravitreal sirolimus, and 71 patients received 880 µg of intravitreal sirolimus every 2 months over 2 years. Subjects with anterior segment involvement were excluded from the 5-month analysis.
The group that received 440 µg of intravitreal sirolimus showed the greatest efficacy, with 60% of patients achieving vitreous haze scores of 0 or 0.5+ without the use of rescue therapy vs. 32.9% in the active control group and 46.5% in the 880 µg group.
There was no significant difference in tapering success rates among the three groups.
“The effect was greater than that seen in the overall intent-to-treat population with patients with posterior segment inflammation only,” Dugel said. “Further studies regarding this are ongoing.” – by Kristie L. Kahl
Reference:
Dugel PU. Intravitreal sirolimus resolves inflammation in noninfectious intermediate or posterior uveitis: SAKURA study 1. Presented at: American Academy of Ophthalmology meeting. Nov. 16, 2015; Las Vegas.
Disclosure: Dugel reports no relevant financial disclosures.